Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease

Lamos, Elizabeth M.; Kristan, Megan; Siamashvili, Maka

doi:10.1080/17512433.2021.1917374

Cited by 7 publications

(3 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…172 The link between NAFLD and metabolic syndrome (especially T2DM) has been described as bidirectional, such that obesity, atherosclerotic hyperlipidemia, hypertension, and T2DM may predict the development of NAFLD and vice versa. 173 Studies have shown that the expression level of HCG18 in the serum of NAFLD patients is significantly higher than that of healthy individuals, and promotes the development of NAFLD. Previously, IL-18 was found to be one of the target genes of miR-197-3p in hepatitis B virus infection.…”

Section: Diabetes-related Diseasesmentioning

confidence: 99%

The role of lncRNA HCG18 in human diseases

Long,

Zhou,

Zhang

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

A substantial number of long noncoding RNAs (lncRNAs) have been identified as potent regulators of human disease. Human leukocyte antigen complex group 18 (HCG18) is a new type of lncRNA that has recently been proven to play an important role in the occurrence and development of various diseases. Studies have found that abnormal expression of HCG18 is closely related to the clinicopathological characteristics of many diseases. More importantly, HCG18 was also found to promote disease progression by affecting a series of cell biological processes. This article mainly discusses the expression characteristics, clinical characteristics, biological effects and related regulatory mechanisms of HCG18 in different human diseases, providing a scientific theoretical basis for its early clinical application.

show abstract

Section: Diabetes-related Diseasesmentioning

confidence: 99%

The role of lncRNA HCG18 in human diseases

Long,

Zhou,

Zhang

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Metformin is the first-line treatment for patients with T2DM, which can control high blood sugar [ 126 ] and decrease total cholesterol, LDL, and triglycerides [ 127 ]. However, the effects of metformin, as well as dipeptidyl peptidase-4 ( DPP-4 ) inhibitors in NAFLD treatment, remain debatable [ 128 ].…”

Section: Treatment Options For Nafld and Nashmentioning

confidence: 99%

Current Options and Future Directions for NAFLD and NASH Treatment

Zhang

Yang

2021

IJMS

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of nonalcoholic steatohepatitis (NASH). Although there are many undergoing clinical trials for NAFLD treatment, there is no currently approved treatment. NAFLD accounts as a major causing factor for the development of hepatocellular carcinoma (HCC), and its incidence rises accompanying the prevalence of obesity and diabetes. Reprogramming of antidiabetic and anti-obesity medicine is a major treatment option for NAFLD and NASH. Liver inflammation and cellular death, with or without fibrosis account for the progression of NAFLD to NASH. Therefore, molecules and signaling pathways involved in hepatic inflammation, fibrosis, and cell death are critically important targets for the therapy of NAFLD and NASH. In addition, the avoidance of aberrant infiltration of inflammatory cytokines by treating with CCR antagonists also provides a therapeutic option. Currently, there is an increasing number of pre-clinical and clinical trials undergoing to evaluate the effects of antidiabetic and anti-obesity drugs, antibiotics, pan-caspase inhibitors, CCR2/5 antagonists, and others on NAFLD, NASH, and liver fibrosis. Non-invasive serum diagnostic markers are developed for fulfilling the need of diagnostic testing in a large amount of NAFLD cases. Overall, a better understanding of the underlying mechanism of the pathogenesis of NAFLD is helpful to choose an optimized treatment.

show abstract

“…The prevalence of NAFLD including liver steatosis and liver fibrosis in T2DM has been estimated to be more considerable 3 , 7 . According to the recent evidence, over fifty percent of individuals with T2DM concurrently have NAFLD 8 , 9 . NAFLD is substantially caused by visceral adipose tissue and insulin resistance 10 .…”

Section: Introductionmentioning

confidence: 99%

Factors related to hypermetabolism in individuals with type 2 diabetes mellitus and non-alcoholic fatty liver disease

Mansour

Motamed²,

Hekmatdoost³

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Considering the progressive prevalence and co-occurrence of type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD), as well as the current evidence suggesting the elevated levels of basal metabolic rate (BMR) among these individuals, the present study aimed to identify factors determining hypermetabolism in such subjects. This cross sectional study was conducted in 30 to 53-year-old individuals with concurrent T2DM and NAFLD (controlled attenuation parameter score ≥ 260 dB/m). Resting energy expenditure (REE) was determined by an indirect calorimetry device. Hypermetabolism was defined as an elevated measured REE > 110% of the predicted REE. The multivariate logistic regression test was used for detecting factors associated with hypermetabolism. Between September, 2017, and March, 2018, a total of 95 eligible participants (64.40% male) with both T2DM and NAFLD were included, while 32.63% of them were classified as hypermetabolic. Overall, the mean recruitment age ± standard deviation and median (interquartile range) body mass index were 44.69 ± 5.47 years and 30.20 (27.80–33.30) kg/m2, respectively. Demographic, anthropometric and biochemical variables did not vary significantly across two groups except for total body water, low-density lipoprotein cholesterol and dipeptidyl peptidase 4 (DPP-4) inhibitors (p < 0.05). According to the results of multivariable logistic regression analyses, hypermetabolism had a positive association with adiponectin (odds ratio [OR] 1.167, 95% confidence interval [CI] 1.015–1.342, p = 0.030), physical activity (OR 1.134, 95% CI 1.002–1.284, p = 0.046), alanine transaminase (OR 1.062, 95% CI 1.006–1.122, p = 0.031) and diastolic blood pressure (OR 1.067, 95% CI 1.010–1.127, p = 0.021). However, fat free mass was inversely related to hypermetabolism (OR 0.935, 95% CI 0.883–0.991, p = 0.023). Adiponectin, alanine transaminase, physical activity, diastolic blood pressure and fat free mass were independently associated with hypermetabolism in subjects with NAFLD and T2DM.

show abstract

Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease

Cited by 7 publications

References 170 publications

The role of lncRNA HCG18 in human diseases

The role of lncRNA HCG18 in human diseases

Current Options and Future Directions for NAFLD and NASH Treatment

Factors related to hypermetabolism in individuals with type 2 diabetes mellitus and non-alcoholic fatty liver disease

Contact Info

Product

Resources

About